MergerAug 6, 2026, 04:35 PM
BioLife Solutions to be Acquired by Repligen
AI Summary
BioLife Solutions, Inc. announced a definitive Merger Agreement with Repligen Corporation, under which Repligen will acquire BioLife for $11.25 in cash and 0.1442 shares of Repligen common stock per share. This agreement will result in BioLife ceasing to be a publicly traded company. The company reported a significant financial turnaround, with Q2 2026 net income of $45.1 million and revenue of $28.5 million, driven in part by a substantial income tax benefit and the absence of prior year's IPR&D expenses. Additionally, the company completed the divestiture of SAVSU in Q4 2025, generating a $10.3 million gain, and acquired the remaining 90% of PanTHERA in April 2025.
Key Highlights
- BioLife Solutions to be acquired by Repligen for $11.25 cash and 0.1442 Repligen shares per share.
- Q2 2026 net income from continuing operations was $45.1 million, compared to a $15.3 million loss in Q2 2025.
- Q2 2026 revenue increased 21.4% to $28.5 million from $23.4 million in Q2 2025.
- Net income for the six months ended June 30, 2026, was $46.3 million, compared to a $16.3 million loss in the prior year.
- Revenue for the six months ended June 30, 2026, grew 23.0% to $56.0 million from $45.5 million in the prior year.
- Net income for Q2 and YTD 2026 was significantly boosted by a $42.3 million income tax benefit.
- Cash, cash equivalents, and available-for-sale securities totaled $113.1 million as of June 30, 2026.
- The company recognized a $10.3 million gain from the SAVSU divestiture in Q4 2025.
- The company acquired the remaining 90% of PanTHERA in April 2025 for a total closing cost consideration of $16.8 million.
Price Impact
More from BLFS